In this study, we determined whether the levels of miR-21, miR-10b, and miR-19a in the serum of breast cancer patients would be useful as diagnostic and prognostic biomarkers for patients with IBC and HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.